Latest Insider Transactions at Vir Biotechnology, Inc. (VIR)
This section provides a real-time view of insider transactions for Vir Biotechnology, Inc. (VIR). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Vir Biotechnology, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Vir Biotechnology, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 09
2022
|
Vicki L Sato Director |
SELL
Open market or private sale
|
Direct |
14,541
-0.96%
|
$290,820
$20.62 P/Share
|
|
Apr 28
2022
|
Vicki L Sato Director |
SELL
Open market or private sale
|
Direct |
17,915
-0.58%
|
$376,215
$21.12 P/Share
|
|
Apr 15
2022
|
Phillip Pang EVP & Chief Medical Officer |
SELL
Bona fide gift
|
Direct |
7,777
-4.96%
|
-
|
|
Mar 30
2022
|
Ann M. Hanly EVP & Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
2,627
-3.12%
|
$68,302
$26.24 P/Share
|
|
Mar 10
2022
|
George A Scangos Director |
BUY
Grant, award, or other acquisition
|
Direct |
111,000
+33.14%
|
-
|
|
Mar 10
2022
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
9,000
+4.65%
|
$9,000
$1.53 P/Share
|
|
Mar 02
2022
|
Johanna Friedl Naderer EVP & Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
90,000
+50.0%
|
-
|
|
Feb 22
2022
|
Howard Horn CFO |
BUY
Grant, award, or other acquisition
|
Direct |
35,000
+12.94%
|
-
|
|
Feb 22
2022
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
1,375
-0.78%
|
$41,250
$30.0 P/Share
|
|
Feb 22
2022
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,375
+0.77%
|
$1,375
$1.53 P/Share
|
|
Feb 22
2022
|
Herbert Virgin EVP, Research & CSO |
BUY
Grant, award, or other acquisition
|
Direct |
70,000
+28.52%
|
-
|
|
Feb 22
2022
|
Steven J. Rice Chief Administrative Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+34.1%
|
-
|
|
Feb 22
2022
|
Phillip Pang EVP & Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
67,000
+29.94%
|
-
|
|
Feb 22
2022
|
Ann M. Hanly EVP & Chief Technology Officer |
BUY
Grant, award, or other acquisition
|
Direct |
53,500
+38.88%
|
-
|
|
Feb 18
2022
|
George A Scangos Director |
SELL
Open market or private sale
|
Direct |
17,726
-13.56%
|
$531,780
$30.65 P/Share
|
|
Feb 17
2022
|
Howard Horn CFO |
SELL
Open market or private sale
|
Direct |
2,393
-1.18%
|
$74,183
$31.93 P/Share
|
|
Feb 17
2022
|
Steven J. Rice Chief Administrative Officer |
SELL
Open market or private sale
|
Direct |
1,942
-9.43%
|
$60,202
$31.93 P/Share
|
|
Feb 17
2022
|
George A Scangos Director |
SELL
Open market or private sale
|
Direct |
10,024
-7.12%
|
$310,744
$31.93 P/Share
|
|
Feb 17
2022
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
2,293
-2.13%
|
$71,083
$31.93 P/Share
|
|
Feb 17
2022
|
Phillip Pang EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,009
-3.24%
|
$93,279
$31.93 P/Share
|
|
Feb 16
2022
|
Phillip Pang EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,000
-5.11%
|
$155,000
$31.54 P/Share
|
|
Feb 16
2022
|
Phillip Pang EVP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+4.86%
|
$5,000
$1.53 P/Share
|
|
Feb 08
2022
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
1,375
-1.26%
|
$45,375
$33.94 P/Share
|
|
Feb 08
2022
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,375
+1.24%
|
$1,375
$1.53 P/Share
|
|
Feb 02
2022
|
Phillip Pang EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,000
-5.11%
|
$170,000
$34.52 P/Share
|
|
Feb 02
2022
|
Phillip Pang EVP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+4.86%
|
$5,000
$1.53 P/Share
|
|
Jan 25
2022
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
1,375
-1.26%
|
$44,000
$32.46 P/Share
|
|
Jan 25
2022
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,375
+1.24%
|
$1,375
$1.53 P/Share
|
|
Jan 19
2022
|
Phillip Pang EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,000
-2.59%
|
$175,000
$35.06 P/Share
|
|
Jan 19
2022
|
Phillip Pang EVP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+4.86%
|
$5,000
$1.53 P/Share
|
|
Jan 18
2022
|
Vicki L Sato Director |
SELL
Open market or private sale
|
Direct |
15,173
-0.98%
|
$561,401
$37.39 P/Share
|
|
Jan 11
2022
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
1,375
-1.26%
|
$48,125
$35.1 P/Share
|
|
Jan 11
2022
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,375
+1.24%
|
$1,375
$1.53 P/Share
|
|
Jan 05
2022
|
Phillip Pang EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,000
-2.57%
|
$185,000
$37.46 P/Share
|
|
Jan 05
2022
|
Phillip Pang EVP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+4.86%
|
$5,000
$1.53 P/Share
|
|
Dec 28
2021
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
1,375
-1.26%
|
$53,625
$39.95 P/Share
|
|
Dec 28
2021
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,375
+1.24%
|
$1,375
$1.53 P/Share
|
|
Dec 20
2021
|
Arch Venture Partners Ix, LLC > 10% Shareholder |
BUY
Other acquisition or disposition
|
Direct |
61,207
+28.46%
|
-
|
|
Dec 20
2021
|
Arch Venture Partners Ix, LLC > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
1,750,000
-8.47%
|
-
|
|
Dec 20
2021
|
Robert Nelsen Director |
BUY
Other acquisition or disposition
|
Direct |
102,041
+29.47%
|
-
|
|
Dec 20
2021
|
Robert Nelsen Director |
SELL
Other acquisition or disposition
|
Indirect |
1,750,000
-8.47%
|
-
|
|
Dec 20
2021
|
Svf Endurance (Cayman) LTD > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
400,022
-1.77%
|
$20,801,144
$52.73 P/Share
|
|
Dec 20
2021
|
Vicki L Sato Director |
SELL
Open market or private sale
|
Direct |
15,174
-0.19%
|
$834,570
$55.1 P/Share
|
|
Dec 15
2021
|
Phillip Pang EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,000
-1.3%
|
$250,000
$50.88 P/Share
|
|
Dec 15
2021
|
Phillip Pang EVP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+4.86%
|
$5,000
$1.53 P/Share
|
|
Dec 15
2021
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
2,750
-2.49%
|
$137,500
$50.0 P/Share
|
|
Dec 15
2021
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,750
+2.43%
|
$2,750
$1.53 P/Share
|
|
Dec 14
2021
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
1,375
-1.26%
|
$61,875
$45.88 P/Share
|
|
Dec 14
2021
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,375
+1.24%
|
$1,375
$1.53 P/Share
|
|
Dec 01
2021
|
Phillip Pang EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,500
-1.91%
|
$322,500
$43.59 P/Share
|